Kawasaki Disease: Early Detection & Treatment
Understand Kawasaki Disease: the primary cause of acquired heart disease in children in developed countries. early diagnosis and treatment are critical, learn what is happening now with advanced cardiac imaging and risk assessments.This informative article explores key symptoms like fever and rash, and the importance of Z-scores in detecting coronary artery abnormalities. Discover how intravenous immunoglobulin (IVIG) is still the standard treatment, learn about new approaches for treatment-resistant cases, including the roles of corticosteroids, and explore the differences with Multisystem Inflammatory Syndrome in Children (MIS-C). News Directory 3 provides the latest updates. Discover what’s next in the fight against Kawasaki Disease.
Advances Improve Kawasaki Disease Diagnosis and Treatment
Updated June 29, 2025
Notable strides in cardiac imaging and risk assessment have led to better diagnosis, initial treatment, and long-term care for patients wiht Kawasaki Disease, according to a report in Circulation. Kawasaki Disease, a rare but serious illness, primarily affects children younger than 5 years old.
The condition inflames blood vessels and is the leading cause of acquired heart disease in children in developed countries. While the cause remains unknown, an infectious origin is suspected. Diagnosis relies on recognizing symptoms like prolonged fever, rash, reddened eyes, and swelling of extremities.
Without prompt treatment, about 25% of children with Kawasaki Disease develop coronary artery dilation or aneurysms. Doctors use coronary artery Z-scores to assess coronary abnormalities, comparing a child’s artery diameter to that of healthy children. A Z-score above 2.5 indicates increased risk.
Early identification of children at risk for coronary artery aneurysms remains challenging. A new risk scoring system for North American children considers factors like age under 6 months, Asian ethnicity, elevated Z-scores, and high C-reactive protein levels to identify high-risk patients needing intensive treatment.
Echocardiograms at regular intervals, especially for those with Z-scores above 2.5, help monitor the progression of abnormalities. Improved echocardiographic techniques enhance detection of coronary artery dilation or aneurysms,preventing long-term heart problems.
Intravenous immunoglobulin, or IVIG, remains the standard treatment for Kawasaki Disease. Studies suggest that adjusting IVIG dosages based on lean body mass in obese patients can reduce complication risks. The role of aspirin is also being re-evaluated, with recent studies suggesting that low- or medium-dose aspirin may be as effective as high-dose aspirin.
For children at high risk of IVIG resistance, adding corticosteroids or infliximab may help prevent coronary artery complications. For those with large coronary aneurysms,blood thinners like aspirin and anticoagulants may prevent hazardous clots. Direct oral anticoagulants may be more effective and safer, but further research is needed.
The COVID-19 pandemic saw a rise in Multisystem inflammatory Syndrome in Children (MIS-C), which shares symptoms with Kawasaki Disease. Key differences include gastrointestinal issues, low platelet counts, and low white blood cell counts in MIS-C. Coronary artery involvement remains a hallmark of Kawasaki Disease. Machine learning algorithms may help differentiate between the two conditions.
What’s next
Medical centers treating Kawasaki Disease with giant coronary artery aneurysms should have multidisciplinary heart teams and protocols for cardiac events. A formal transition program is needed for adolescents and adults with a history of Kawasaki Disease, as those with giant aneurysms face a high risk of heart attack and require lifelong monitoring. Pregnant individuals with Kawasaki Disease need specialized obstetric and cardiology care.